Speakers

Wayne Swanton has held multiple roles at Abbott Laboratories over the last 20 years, both within supply chain and finance. Originally based in the UK, Wayne held planning, project management, and controller positions over both manufacturing and commercial operations

Relocating in 2001 to Abbott's US headquarters in Chicago, Wayne has held global pharmaceutical roles with responsibilities for Planning, Logistics, Network restructuring and most recently creating a new organization aligned by commercial franchise to drive supply chain strategy in key brands.
Wayne graduated from the UK in Finance and is a fellow of the Chartered Association of Certified Accountants. Interests outside of work include golf and wine.

Hussain Mooraj brings more than 15 years of experience in manufacturing, supply chain, life sciences consulting, strategy consulting, strategic marketing, and technology consulting to his role. He works closely with executives from companies across the healthcare value chain (manufacturers, wholesalers, pharmacies, payers, and providers) advising them on business strategy and technology best practices. He has been selected by PharmaVOICE as one of the top 100 most inspirational and influential people in the life sciences industry in 2009.

Prior to joining AMR Research, Hussain was heading the program management, marketing and business development functions for Trinity Partners LLC and Trinity Pharma Solutions LLC, firms specializing in strategic consulting and technology-based data management solutions for global pharmaceutical and biotech companies.

Hussain also worked as an engagement lead at Zefer Corporation. While there, Hussain helped Fortune 500 companies develop their B2B and technology strategies.

Hussain founded two global textile manufacturing companies where he served on the Board of Directors and was responsible for strategy, manufacturing and sourcing, new product development, and global sales and marketing.

Hussain earned his BS in textile management, with honors, from Clemson University/Textile University of Pakistan. He also holds an Engineering MS in Information Systems, an MBA, and a graduate certificate in Supply Chain Management from Northeastern University. He also teaches at Brandeis University and is a guest lecturer at Northeastern University.

Speaker overview coming soon...

Kris joined Nielsen in 2000 with forecasting and client responsibilities in the carbonated beverage, fast food, and pharmaceutical industries. He assumed an ex-pat role in the Mexico City office from 2002-2004 focused on forecasting of new consumer package goods. For that past 5 years following his return to the US , he has been dedicated to the research and development of NielsenBASES’ pharmaceutical forecasting models. 

Mark Morgan is currently the Vice-President of Finance for North American Service Level Agreement management for Bayer Health Care. In this role, Mr. Morgan manages a $100 million budget for internal service agreements impacting information systems and services across Bayer’s Health Care divisions.

Previously, Mr. Morgan was the head of finance for the $1.5B Diabetes Care business of Bayer Healthcare.  In this role, Mr. Morgan oversees the global finance function for the fastest growing business within the diabetes business segment. Bayer Healthcare has succeeded in nearly doubling the revenue and tripling the profits for this business in just four years.

Prior to joining Bayer Healthcare, Mr. Morgan was active in a consulting business he founded, The Hypernicon Group. His company assisted pharmaceutical companies in assessing business plans and managing acquisition integration.

Mr. Morgan has significant experience working with major systems, including many SAP implementations, and major business processes including Sales and Operations Planning (S&OP) and Balanced Scorecard performance measures.

Mr. Morgan has over 30 years of professional experience in finance leadership roles with top tier firms including Pfizer, SC Johnson Wax and Mylan Pharmaceuticals.

Mr. Morgan has been published five times and his publications have twice received writing honors.  Mr. Morgan is a distinguished alumni of his undergraduate alma mater, Indiana State University. He also holds an MBA from Illinois State University where he graduated with highest honors.

Mr. Morgan is an avid gardener, outdoorsman and writer. He is also a cancer survivor.

Speaker overview coming soon...

Speaker overview coming soon...

Michael Turner brings over 14 years of experience in strategy and finance, including nine years of marketing and sales strategy experience in biopharmaceutical consulting, to Campbell Alliance, where he assists clients with new product commercialization and launch, strategic brand and portfolio planning and organization capability development.

Before joining Campbell Alliance, Mr. Turner served as a Director with marketRx, Inc., a technology-focused analytics and market research consulting firm for biotech and pharmaceutical companies. He has been a Consultant for ZS Associates, a strategic consulting firm, and has worked for the Federal Reserve Bank of New York.

Mr. Turner holds an MBA with an emphasis in Corporate Strategy and Marketing from the University of Michigan Business School, where he graduated with high distinction. He received his Bachelor of Science degree in Operations Research and Engineering from Cornell University in Ithaca, NY.

Mr. Cast is the Vice President of Specialty Pharmaceutical Sales at CuraScript, Inc. He joined the CuraScript Management Team in February of 2003 to develop CuraScript Biotech Solutions, a division built to capitalize on the expertise amassed within CuraScript regarding biological product launches and limited distribution support programs.

A wholly owned subsidiary of Express Scripts (ESI), CuraScript offers a fully integrated solution for pharmaceutical manufacturers including specialty pharmacy, specialty distribution, and Pharma support services (PAP, Reimbursement HUBs, etc).  CuraScript is a well established industry leader in the Specialty Pharmaceutical market.

For the past 20 years, Mr. Cast has been involved in biotech manufacturer sales, formerly  as the Director of National Accounts at Serono, Inc. In that role he gained valuable insight into the requirements of a successful partnership between Biotech Manufacturers and Specialty Pharmacy Providers. 

Mr. Cast holds a BA in Biology from Illinois Wesleyan University and Masters in Botany from Oklahoma State University. He is an active member of the PCMA Specialty Pharmacy Board of Governors, and involved in many other industry committees.

Dr. Robert Carbone received his doctorate from Carnegie-Mellon University. He co-developed the Carbone-Longini AEP filter which contributed to the application of Adaptive Filtering methods in forecasting. He founded The International Institute of Forecasters with Dr. Scott A. Armstrong, Dr. Robert Fildes, and Dr. Spyros Makridakis. A leading academic, Dr. Carbone served for several years as editor of the Journal of Forecasting and he co-developed the Carbone-Makridakis forecasting system (CMFS) introduced in Management Science, Vol. 32, No. 3, 1986.

Dr. Carbone has been presiding over Futurion, a worldwide provider of forecasting technology and consultancy for more than 20 years. In this venture, Dr. Carbone has been involved in the design and implementation of forecasting solutions and processes in hundreds of companies of all sizes, in all industries. More specifically in the pharmaceutical industry, he has assisted companies such as AstraZeneca, Amgen, Hoechst Roussel, Janssen, E.R. Squibb, Marion Merrell Dow, Novopharm, Bayer, SmithKline and French, Burroughs Wellcome, Glaxo, GSK, Syntex, Sterling Drugs, Sanofi Aventis, Ciba Geigy, Sandoz, Merck & Co., Boehringer Ingelheim, Ortho McNeil, Roche, Wyeth and Novartis in establishing effective forecasting processes.

Radi Haloub is currently a PhD student at the University of Huddersfield / Business School. His main research focus is Pharmaceutical Sales Forecasting.

Previously, Mr. Haloub was assigned as a Key Account Manager (for key account pharmacy chain) in IATCO – Procter and Gamble Distributor in Saudi Arabia. In this role, he was responsible for managing customer sales, customer business development, employing and training of sales team, market analysis and managing outlets distribution. 

Prior to joining IATCO, Mr. Haloub worked in Hikma Pharmaceuticals for more than 8 years in various sales and marketing positions in Jordan and Saudi Arabia. In Jordan, Mr. Haloub was responsible for building new line products in Hikma Pharmaceuticals in MENA countries (Middle East and North Africa), planning and conducting marketing research, training sales teams, contacting international suppliers, launching and re-launching new and existing products in different MENA countries and re-positioning existing products.

In 2005, Hikma Pharmaceutical’s management nominated Mr. Haloub to re-launch its image in the Saudi market, where he became responsible for the sales and marketing activities of injectable products in the Saudi Arabian Market / Western Area. Mr. Haloub managed to accomplish a doubling in the injectable product’s sales in the western area within 2 years, employ a new injectable team and train them about hospital and institutional selling skills in addition to launching of new injectable items.

The University of Huddersfield granted Mr. Haloub a full-tuition PhD scholarship for the duration of 36 months, where he is currently conducting a novel research in pharmaceutical sales forecasting that is expected to result in a prescriptive model for a theoretical conceptual stage in the process of sales forecasting, and an understanding of how Bayesian theory can be utilized to improve the predictive capabilities of pharmaceutical companies.

Mr. Haloub holds a BA in Pharmacy from Amman University and a Masters in Marketing from University of Huddersfield. He is a member of the Chartered Institute of Marketing and a Chartered Marketer.

Charles comes to Johnson & Johnson’s Washington, DC office after six years as the head of ALZA’s Government Affairs operations, nearly thirty years of experience in the pharmaceutical industry and over forty years of active political involvement. Charles’ focus is on pharmaceutical pricing and access issues, federal proposals affecting
drug delivery technology and California’s congressional delegation.
Before establishing ALZA Government Affairs, Charles was General Counsel of Syntex Laboratories (1983-1995) and an associate at the Wall Street firm of Cahill, Gordon & Reindel (1973-1983). Charles ran the American side of Cahill’s Paris office for several years, negotiating
agreements (often for PhRMA clients) in countries throughout both Eastern and Western Europe, the then-Soviet Union and Africa. Charles has served as an advisor to the National Institute of Drug abuse and the European Economic Community on AIDS and disability law.
Charles graduated summa Cum Laude from the University of Notre Dame (BA, Government and International Relations) and received his law degree from the University of Notre Dame Law School.

Speaker overview coming soon...

Mary Bordeaux is an independent consultant with offices in San Francisco, CA. Her practice, Mary Bordeaux Consulting, was established in 2002 with a focus on coverage / reimbursement / distribution strategies for small and emerging companies and emerging technologies.  She has over 30 years in the pharmaceutical industry. Client projects span the development, acquisition, and commercialization phases of company and product life cycles. Her client base is throughout the U.S.  Her last industry position was as Vice President of Health Systems for ALZA Corporation.

Todd R. Johnson has been Director of Forecasting at MattsonJack for the past two years. Mr. Johnson has more than 20 years of experience in the pharmaceutical industry. Prior to joining MattsonJack, he held increasingly responsible positions at sanofi-aventis in marketing research, forecasting, managed care, product management, and sales leadership. Mr. Johnson has a B.S. in Business Administration and an M.B.A. from the University of Arizona.

Mr. Lee Blansett, Senior Vice President, Oncology Market Access, leads MattsonJack’s U.S. market access practice. Mr. Blansett’s work focuses on market access topics for cancer drugs and covers commercial and public reimbursement, government policy, managed care, and provider economics in the U.S. and the EU. His provider and plan experience includes current work with oncology medical groups and prior work with Stanford Medical Center, Kaiser Foundation Health Plans / The Permanente Medical Group, and APM. Mr. Blansett earned a B.Sc. in Finance at Santa Clara University, where he was a National Merit Scholar, and an M.B.A. in Entrepreneurial Studies at The Wharton School, University of Pennsylvania.

Speaker overview coming soon...

Prior to his current role as President of Scarsin, Mr. Minshull worked with Eli Lilly in a number of Marketing and Business Development roles including CNS Team Leader overseeing a portfolio of products.  It was in these formative years that Mr. Minshull gained an understanding of how valuable quality analytics could be in supporting good business decisions.  

After venturing out to pursue entrepreneurial interests in 1996, Mr Minshull continued to encounter similar process inefficiencies across analytic projects with more than 20 clients in more than 25 therapeutic areas in Canada, the US and Europe.  As a result, Mr. Minshull started Scarsin in 2001 to focus on developing an enabling enterprise technology to help clients conduct more efficient reporting and forecasting.  Since then he has overseen the development and deployment of an enterprise class solution that has helped many successful global brands achieve greater insights on their business, helping them make better decisions.  

Mr. Minshull holds a B.Comm and an MBA in finance from McMaster University.

Ms. Sarah Nguyen received her Master of Arts in Economics from New Mexico State University.  She has worked in the Pharmaceutical industry for 2.5 years at Solvay Pharmaceuticals, Inc., where she is the Decision Science Manager.  In this role, she and her team support the Commercial Operations organization through the development of price elasticity and sampling models, measuring the effectiveness and ROI of marketing programs, and forecasting for in-line, pipeline, and new business development opportunities.

Prior to her career at Solvay, Sarah worked in several industries, including wireless communications, energy, and high-tech.  Her responsibilities included forecasting, customer segmentation, response modeling, and campaign management.

Partha Anbil is Practice Leader, Pharma Solutions at Wolters Kluwer Health and an Adjunct Professor, Fox School of Business & Management, Temple University, PA. He has over two decades of Management Consulting and Organizational experience -- as Senior Principal at IMSHealth (NYSE: Rx), Principal at Bearingpoint formerly KPMG consulting, PricewaterhouseCoopers (PwC) LLP and Deloitte Consulting. He has consulted & counseled Life Sciences clients in structuring solutions for strategic, operational & organizational challenges and issues. Mr. Anbil counseled Life Sciences clients on different commercial effectiveness strategies based on Market, Product and Company Characteristics, as well as Regulatory Environment.

He has multi-disciplinary educational background and cross-functional experience. Mr. Anbil received an MBA in Corporate Strategy and Business Development from the MIT Sloan School of Management, Cambridge, Massachusetts, and an M.S. in Corporate Finance and M.A. in Economics & Econometrics from the University of Toledo, Toledo, OH. He also has an M.I.B (Masters in International Business) from the Indian Institute of Foreign Trade (IIFT), and a B.S. in Electrical Engineering.

He is active in academia and is an adjunct professor at the Fox School of Business and Management, Temple University, PA teaching Executive MBA program. The courses taught include: Capstone course on Competitive Strategy and Global Strategy and Customer Relationship Management. He is actively associated with the Mack Center (Industry-Academic Forum), at the Wharton School of Business. Mr. Anbil speaks at the various industry related conferences such as American Marketing Association (AMA), Pharmaceutical Marketing Sciences Association (PMSA), Pharmaceutical Marketing Research Group (PMRG), Synygy’s Sales Performance, PharmaIQ, and other conferences organized by CBI, EyeforPharma, Pharmaforce, Jacob Fleming, exlpharma and Marcus Evans, etc. In the thought leadership arena, he had published many articles in business journals and magazines such as PharmaVoice, PMT etc and contributed internal white papers for the consulting firms he had worked.

Art Cook is a Principal with ZS Associates in Los Angeles, CA. His experience is in strategic planning, forecasting, market research, pricing and decision analysis.  He has worked with pharmaceutical companies across 25 countries in North America, Latin America, Asia, Europe and Australia and has developed forecasts for products in over 150 different therapeutic areas. Art’s experience prior to joining ZS Associates includes positions at two major pharmaceutical companies.  He also has been a featured speaker at numerous pharmaceutical and health care industry conferences and is the author of the 2006 text entitled “Forecasting for the Pharmaceutical Industry.”

Art holds an MBA from the University of California at Berkeley, a PhD in Chemistry from Harvard University, and a BS in Chemistry from Stanford University.

Eric von Hippel is T Wilson Professor of Innovation Management and Professor of Engineering Systems at MIT.  His academic research examines the sources and economics of innovation. His most recent book, "Democratizing Innovation" (MIT Press, 2005) is available free on the web ( http://mit.edu/evhippel/www/books.htm )

Marie E Lamont joined Genzyme in 1993 and oversees and directs all aspects of International Finance and Operations. Her International areas of responsibility include: Accounting & Controls, IT, Customer Service, Supply Chain, Reporting and Financial Planning & Analysis. Ms. Lamont has held positions of increasing responsibility at Genzyme as International Controller, Director of Corporate Financial Planning & Analysis, Product Line controllership and in the treasury department. Prior to joining Genzyme, Ms. Lamont was Assistant Treasurer at Clearpoint Research Corporation/Clearpoint, Inc.

Ms. Lamont volunteers actively with the Junior League of Boston and also the Department of Children and Families as a volunteer Foster Care Case Reviewer. She has been involved with Boston Women in Finance (formerly FWA of Boston) as a member since its inception. Ms. Lamont has a B.S. from Saint Michael’s College in Vermont.

Ragu Bharadwaj works as a Research Scientist who is applying systems methods and lean techniques over the Research, Development and Commercialization areas at Vertex Pharmaceuticals, Cambridge MA. Prior to Vertex Ragu worked at Amphora Discovery Corporation, a microfluidics-based drug discovery company, and at Daylight Chemical Information Systems, a cheminformatics company. He received his Ph.D. in Biochemistry from Columbia University in 1996 and his M.S. in Systems Design & Management from MIT in 2009. His research interests include market- and open-innovation-based mechanisms to incentivize value creation in the pharma domain.

Peter Coles is a member of the Negotiation, Organizations, and Markets Unit at Harvard Business School. He received his A.B. in mathematics from Princeton University and his PhD in economics in 2006 from Stanford University.

His current research deals with market design, and especially the incentives for participants in online marketplaces.  Peter has recently written cases on prediction markets at Google, strategy at Microsoft's adCenter, pricing and the "market ecosystem" at TheLadders.com, and on several other topics.  Current projects include the design of a prediction market for drug clinical trials, as well as analysis of a signaling mechanism he helped design for the American Economics Association to streamline the job market for economists.

Along with Professor Ben Edelman, Peter teaches "Managing Networked Businesses," a second year course at Harvard Business School.  With Professor Al Roth he co-teaches a doctoral course in market design in the Harvard Economics Department.

Fiona Murray is an Associate Professor of Management in the Technological Innovation and Entrepreneurship Group at the MIT Sloan School of Management.   She received BA and MA degrees from the University of Oxford in Chemistry before coming to the United States where she received her doctoral degree from Harvard University’s School of Engineering and Applied Sciences.  Her research interests then moved away from the bench to the study of science commercialization, the organization of scientific research and the role of science in national competitiveness. After a short time on the faculty of Oxford’s Said Business School Fiona joined the MIT Sloan School of Management where she studies and teaches innovation and entrepreneurship with an emphasis on the life sciences sector. Fiona is well-known for her work on how growing economic incentives, particularly intellectual property (IP), influence the rate and direction of scientific progress, particularly in the areas of genomics, stem cells, and mouse genetics.  Fiona works with a range of firms designing global organizations working with a wide range of internal and external innovators (through traditional contracts and “Open Innovation” mechanisms) that are both commercially successful and at the forefront of science. She is also actively involved in policy debates over the appropriate use of IP and licensing in universities and more recently debates on when and when not to use patents to promoted discovery research in neglected diseases. She is also interested in new emerging organizational arrangements for effective commercialization of science including public-private partnerships, not-for profits, venture philanthropy, and university-initiated seed funding.  In particular, Fiona has made an extensive examination of investments in a broad range of institutional arrangements to support scientific productivity both in the US and beyond in emerging science-based nations such as China and India.  Her research has been widely published in a diverse range of scientific and social science journals including Science, New England Journal of Medicine, Nature Biotechnology, Research Policy, Organization Science and the Journal of Economic Behavior & Organization.

Bob has nearly 20 years of experience in forecasting across multiple industries (pensions, automotive, food, drinks) but for the last 12 years has been focused on the pharmaceutical industry.  Bob began his career as an actuary in the UK, then following a few years in consultancy, moved to Eli Lilly in Indianapolis where he has led the Global Forecasting Group since 2000.  His role encompasses long range strategic planning , decision support and new product forecasting throughout development.   Bob has an MA in mathematics from Oxford University.